Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLN-254 in Relapsed or Refractory T-cell Lymphoma
NCT06733441Phase 1Active, not recruiting
- Sponsor
- Treeline Biosciences
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of TLN-254 in T-cell lymphoma (2 cohorts), sponsored by Treeline Biosciences. Primary endpoints: Objective Response Rate up to 2 years, Complete Response up to 2 years and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
TLN-254
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT06733441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733441.